NICE backing for AZ' Tagrisso
AstraZeneca's Tagrisso (osimertinib) has been recommended for use within NHS England, in line with its licensed indication, for adults with untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
In clinical trials, the drug was shown to provide an overall survival benefit of more than three years when used as a first-line treatment compared to first-generation medicines in the same class.
Clinical data also show that Tagrisso has a more significant impact on cancer that has spread to the central nervous system and a favourable side effect profile, AZ noted.
Lung cancer is currently the most common cause of cancer death in the UK, accounting for one in five (21%) of all cancer deaths.
Read more: http://www.pharmatimes.com/news/nice_backing_for_az_tagrisso_1350193
In clinical trials, the drug was shown to provide an overall survival benefit of more than three years when used as a first-line treatment compared to first-generation medicines in the same class.
Clinical data also show that Tagrisso has a more significant impact on cancer that has spread to the central nervous system and a favourable side effect profile, AZ noted.
Lung cancer is currently the most common cause of cancer death in the UK, accounting for one in five (21%) of all cancer deaths.
Read more: http://www.pharmatimes.com/news/nice_backing_for_az_tagrisso_1350193
